Treatment with avasimibe was sufficient to remove CE in Ba/F3 BCR-ABLWT cells (S1D and S1E Fig), suggesting the potential of targeting cholesterol metabolism in BCR-ABL driven CML. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.